Menu Search
Equities

Mega Lifesciences PCL

  • Add to watchlist
  • Add to portfolio
  • Add an alert
MEGA:SET

Mega Lifesciences PCL

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (THB)38.75
  • Today's Change0.00 / 0.00%
  • Shares traded719.10k
  • 1 Year change+20.16%
  • Beta0.6781
Data delayed at least 15 minutes, as of Feb 20 2026.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 20-Feb-25
  • 20-Nov-25
  • 18-Dec-25
  • 15-Jan-26
  • 19-Feb-26
Select bar for recommendation details.
Recommendations19-Feb-26
Buy1
Outperform3
Hold3
Sell0
Strong Sell0

Share price forecast in THB

The 8 analysts offering 12 month price targets for Mega Lifesciences PCL have a median target of 37.25, with a high estimate of 47.60 and a low estimate of 26.00. The median estimate represents a -3.87% decrease from the last price of 38.75.
High22.8%47.60
Med-3.9%37.25
Low-32.9%26.00

Dividends

In 2024, Mega Lifesciences PCL reported a dividend of 1.60 THB, equaling last years dividend. The 7 analysts covering the company expect dividends of 1.55 THB for the upcoming fiscal year, a decrease of 3.38%.
Note: The percentage change is calculated using unrounded (raw) dividend values.
Div growth (TTM)0.00%
More ▼

Earnings history & estimates in THB

On Nov 13, 2025, Mega Lifesciences PCL reported 3rd quarter 2025 earnings of 0.57 per share. This result exceeded the 0.49 expectation of the one analyst covering the company and exceeded last year's 3rd quarter results by 29.55%.
The next earnings announcement is expected on Feb 23, 2026.
Average growth rate+12.91%
Mega Lifesciences PCL reported annual 2024 earnings of 2.31 per share on Feb 24, 2025.
Average growth rate+11.15%
More ▼

Revenue history & estimates in THB

Mega Lifesciences Public Company Limited had 3rd quarter 2025 revenues of 3.88bn. This bettered the 3.73bn consensus of the 2 analysts covering the company. This was 3.85% above the prior year's 3rd quarter results.
Average growth rate-0.24%
Mega Lifesciences Public Company Limited had revenues for the full year 2024 of 15.34bn. This was 2.15% below the prior year's results.
Average growth rate+5.27%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.